Velculescu cautions that medical practice may not change much until additional studies validate their findings, and there are
ongoing clinical trials studying the removal of fallopian tubes instead of ovaries in women with cancer - causing, hereditary BRCA1 and BRCA2 mutations.
Not exact matches
There are about 120
studies ongoing in Israel, including
clinical trials looking at the effects of cannabis on autism, epilepsy, psoriasis, and tinnitus.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to
ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from
clinical trials involving investigational compounds; Gilead's ability to initiate
clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from
clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Physicians immediately began recruiting hundreds of people for a
clinical trial of the drug, and that
study is
ongoing.
These findings also suggest a mechanistic basis for potential treatments involving the painless electrical stimulation of the amygdala, which are currently being
studied in
ongoing clinical trials.
The first
clinical trial was a safety
study in Australia, followed by an
ongoing efficacy
study in Peru to evaluate the ability to treat patients with malaria.
She is currently a Research Fellow who is
studying the immunological and virological characterization of HIV -1-infected patients who are taking antiretroviral therapy and various viral reactivation agents in several
ongoing clinical trials.
A recent grant from the National Institutes of Health's National Heart, Lung and Blood Institute is allowing Felder and his colleagues to continue their
studies, and they are now seeking volunteers for their
ongoing salt consumption
clinical trials.
Ward et al. highlight results from molecular and preclinical
studies, discuss
clinical trial results to date, describe
ongoing investigations, and assess novel approaches for the enhancement of MSC based cardiac regeneration, such as genetic modification.
Dr. Powers completed a
clinical drug safety
trial for the use of Advantage Multi for Cats (Bayer) in domestic ferrets, and has conducted several other research
studies while at Carolina Veterinary Specialists, including an investigation into the metabolism of the anticonvulsant drug phenobarbital in African grey parrots and
ongoing studies investigating a newly characterized intestinal parasite of cockatiels, Spironucleus meleagridis.
There are several
clinical trials and many
ongoing research
studies for animals with oral tumors.
Currently, Dr. Wittenborn is
studying the effectiveness of Emotionally Focused Therapy for couples with comorbid depression and relationship distress in an
ongoing randomized
clinical trial.